论文部分内容阅读
目的评价小剂量利妥昔单抗联合大剂量地塞米松治疗特发性血小板减少性紫癜的疗效及安全性。方法按照数字随机表法将我院确诊收治的68例特发性血小板减少性紫癜患者分为观察组与对照组,每组各34例,观察组患者给予小剂量利妥昔单抗联合大剂量地塞米松治疗,对照组患者给予大剂量地塞米松治疗,观察两组患者治疗后的相关实验室指标,评价临床疗效,记录不良反应。结果观察组患者治疗后的CD20~+、PAIGG及血小板计数明显优于对照组患者,组间差异有统计学意义(P<0.05)。观察组患者疗效总有效率为91.2%,明显高于对照组患者的73.5%,组间差异有统计学意义(P<0.05)。两组患者治疗过程中均未出现休克、严重感染以及肝肾功能损害等严重并发症。结论小剂量利妥昔单抗联合大剂量地塞米松治疗ITP的临床疗效确切,安全性高,可最为一种理想的治疗方案在临床推广应用。
Objective To evaluate the efficacy and safety of low dose rituximab combined with high dose dexamethasone in the treatment of idiopathic thrombocytopenic purpura. Methods According to the digital random table method, 68 patients with idiopathic thrombocytopenic purpura diagnosed in our hospital were divided into observation group and control group, 34 cases in each group. The patients in observation group were given low dose rituximab combined with high dose Dexamethasone treatment, the control group of patients given high-dose dexamethasone treatment, the two groups of patients after treatment to observe the relevant laboratory indicators, evaluate the clinical efficacy, record adverse reactions. Results After treatment, the scores of CD20 ~ +, PAIGG and platelet in the observation group were significantly better than those in the control group. The difference was statistically significant (P <0.05). The total effective rate of observation group was 91.2%, which was significantly higher than that of control group (73.5%). The difference between the two groups was statistically significant (P <0.05). No severe complications such as shock, severe infection, and liver and kidney dysfunction occurred in both groups during the course of treatment. Conclusion Low dose of rituximab combined with high dose dexamethasone in the treatment of ITP has definite clinical curative effect, high safety and the most ideal treatment plan for clinical application.